Journal of Anesthesiology and Pain Research

Stroke, also known as cerebral dead tissue, is a common disease that seriously impairs neurological function and inhibits respiratory and circulatory function. Every year, a sizable percentage of people have recurrent or new stroke rates. The two most common types of stroke are ischemic and hemorrhagic. Ischemic stroke is the most well-known type. Stroke is one of the top five global causes of death, especially in developed countries and it has a negative financial impact. The development of effective treatment options, particularly for ischemic strokes, is necessary due to these epidemiological and financial implications. Even though there is now no prescription that can effectively lessen the effects of an ischemic stroke, ongoing drug research aims to develop drugs that can both treat and prevent supplementary complications. These drugs aim to improve cell digestion, metabolic function and blood vessel recanalization.

Trigeminal neuralgia (TN) is characterised by transient and unusual episodes of intense face pain that are primarily located in the trigeminal nerve's V2/V3 dermatome (CN V). The disease causes great suffering for some patients and a significant decline in life satisfaction. The measured pervasiveness is between 0.1-0.3%. Traditional TN has frequently been linked to a neurovascular conflict (NVC) at the root section zone between a cerebral vessel (typically the common cerebellar corridor) (REZ).The NVC may cause CNV to separate, demyelinate and deteriorate. According to the first theory, the damaged, demyelinated CNV is incapable of receiving ephaptic transmission of safe somatosensory updates, which activate pain strands and cause excruciating face pain in the associated nerve a region.